Description

Rivotril 2 mg (Clonazepam) Tablets

Rivotril 2 mg is a high-potency, long-acting oral formulation of clonazepam, a chlorinated derivative of the nitrobenzodiazepine class (originally developed by Roche). It functions as a potent positive allosteric modulator at central nervous system $\text{GABA}_A$ receptor complexes. By increasing the frequency of chloride channel opening in the presence of gamma-aminobutyric acid ($\text{GABA}$), it facilitates marked neuronal hyperpolarization, delivering powerful anticonvulsant, anxiolytic, sedative, and central muscle-relaxant effects.

Product Overview

Primary Indications

Rivotril 2 mg is indicated under qualified clinical supervision for:

• Seizure & Convulsive Disorders: Sole agent or adjunctive treatment in the prophylaxis and management of Lennox-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures, absence seizures refractory to succinimides, and generalized tonic-clonic convulsions.

• Panic Disorder: Acute and maintenance treatment of panic disorder, with or without agoraphobia, characterized by recurrent panic attacks and debilitating anticipatory anxiety.

• Refractory Movement Disorders: Adjunctive management of severe akathisia, choreiform disorders, or restless legs syndrome unresponsive to primary therapeutic interventions.

Key Information & Precautions

• High Single-Tablet Strength: Clonazepam is exceptionally potent on a milligram basis (0.5 mg of clonazepam is roughly bioequivalent to 10 mg of diazepam). The 2 mg tablet represents the highest standard oral single-tablet strength and is typically reserved for established, titrated regimens; initial doses for panic or seizure disorders are generally initiated much lower (0.25 mg to 0.5 mg daily) using the tablet’s score lines.

• Cumulative Accumulation: Owing to its prolonged elimination half-life (up to 40 hours), repeated daily administration results in substantial systemic accumulation before steady-state is reached. This significantly elevates the incidence of residual sedation, ataxia, cognitive slowing, and fall risk—particularly in geriatric or debilitated patients.

• Boxed Warning — Abuse, Misuse, and Addiction: Like all high-potency benzodiazepines, clonazepam carries a major liability for physical dependence, psychological tolerance, and non-medical misuse. Long-term therapy should be re-evaluated continuously and restricted to the lowest effective dose.

• Severe Withdrawal Hazard: Abrupt cessation or rapid dose reduction following chronic treatment can precipitate life-threatening withdrawal crises, including status epilepticus, extreme autonomic hyperactivity, delirium, psychosis, and severe rebound anxiety. Discontinuation mandates an individualized, gradual tapering schedule overseen by a physician.

• Boxed Warning — Concomitant CNS Depressants: Co-administration with opioids, alcohol, or other sedative-hypnotics markedly increases the risk of profound central nervous system depression, respiratory arrest, coma, and fatal overdose.

• Loss of Anticonvulsant Efficacy (Tolerance): In the management of epilepsy, some patients experience a gradual loss of seizure control after several months of continuous therapy, necessitating careful dosage re-titration or temporary drug holidays under neurological supervision.

• Cognitive & Psychomotor Impairment: Induces substantial somnolence, decreased reaction time, and impaired motor coordination. Patients must be strictly cautioned against driving, operating heavy machinery, or performing hazardous tasks until their response to the medication is thoroughly established.